XenaCare Holdings Announces Availability of Cobroxin through the Chain Drug Marketing Association (CDMA)

DELRAY BEACH, Fla.--(BUSINESS WIRE)--XenaCare Holdings, Inc. (OTCBB: XCHO.OB), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that the Chain Drug Marketing Association (CDMA) will begin inventorying Cobroxin for redistribution to its member pharmacies. The CDMA currently has over 6,000 independent pharmacy members throughout the United States.

“As one of the largest pharmacy organizations in the United States, we are excited to be working with the CDMA to distribute Cobroxin to its independent pharmacy members,” explained Frank Rizzo, President of XenaCare Holdings. “Having a presence in CDMA member pharmacies will help us build significant awareness about Cobroxin as we continue to expand the brand nationwide through retailers and our multimillion dollar national advertising campaign,” he concluded.

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.